Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor
Solid forms of the compound, 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine, and solid forms of salts or co-crystals of Compound I, were prepared and characterized: Also provided are processes of making the solid forms and methods of use thereof.
1. A crystalline form of Compound I:
wherein the crystalline form is succinate Form I; and
wherein crystalline succinate Form I is characterized by an X-ray powder diffractogram comprising characteristic peaks (°2θ) at 15.2°±0.2°2θ, 18.0°±0.2°2θ, and 20.0°±0.2°2θ.
2. The crystalline form according to claim 1 , wherein the crystalline form is a monoclinic crystalline form having the following unit cell parameters: a equal to 8.62 Å, b equal to 19.71 Å, c equal to 13.46 Å, α equal to 90°, β equal to 108.34°, and γ equal to 90°.
3. The crystalline form according to claim 1 , wherein the crystalline form is further characterized by an X-ray powder diffractogram comprising additional characteristic peaks (°2θ) at 10.8°±0.2°2θ, 20.8°±0.2°2θ, and 24.4°±0.2°2θ.
4. The crystalline form according to claim 1 , wherein the crystalline form is further characterized by a differential scanning calorimetry (DSC) thermogram comprising an endotherm having an onset temperature of 253° C.
5. A pharmaceutical composition comprising the crystalline form according to claim 1 and a pharmaceutically acceptable excipient.
6. A method for inhibiting spleen tyrosine kinase activity in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of the crystalline form according to claim 1 .
7. The method according to claim 6 , wherein the subject suffers from a disease or disorder selected from the group consisting of an allergic disorder, an autoimmune disease, a cancer, and an inflammatory disorder.